YolandaY.YangMDPhD

General Surgery • San Bruno, CA

Physician

Join to view full profile

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Yang's full profile

Already have an account?

Office
---
San Bruno, CA 94066
Is this information wrong?

Education & Training

UC Berkeley ExtensionProfessional Certificate, Clinical Research Conduct and Management, Awarded With Distinction, 2010 - 2011
Cleveland Clinic FoundationFellowship, Hepatobiliary and Pancreatic Surgery, 2004 - 2006
Washington University/B-JH/SLCH ConsortiumResidency, Surgery, 1999 - 2004
Weill Cornell MedicineClass of 1999, MD
The Rockefeller UniversityPhD, 1991 - 1998

Certifications & Licensure

CA State Medical License 2006 - 2025
American Board of SurgerySurgery (2006-2016)
University of California Berkeley ExtensionClinical Research Conduct and Management (Awarded with Distinction)

Awards, Honors, & Recognition

Q3 2014 RETHINK-D Award Genentech/Roche, 2014
President's Award Abbott Vacular, 2012
Department of Surgery Resident Teaching Award Washington University School of Medicine in St. Louis, 2003-2004
The Phi Beta Kappa Award Phi Beta Kappa, 1991
The Rena Gurley Archibald High Scholarship Prize Pomona College, 1991
The Michael H. Rosen Memorial Pre-Med Award Pomona College, 1991
The Vaile Prize in Biology Pomona College, 1991
The Walter Bertsch Prize in Biology Pomona College, 1991
The University of Hawaii Freshman Chemistry Award University of Hawaii at Manoa, 1988
University of Hawaii Regent's Scholar University of Hawaii at Manoa, 1987
Presidential Scholar The US Presidential Scholars Program, 1987
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

SPIRIT Small Vessel Registry Start of enrollment: 2008 Oct 01
Terminated
Not Applicable
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis Start of enrollment: 2010 Sep 01
Completed
Phase 3
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis Start of enrollment: 2011 Mar 01
Completed
Phase 3
EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions Start of enrollment: 2011 Sep 01
Completed
Not Applicable
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy Start of enrollment: 2011 Oct 01
Completed
Not Applicable
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 2
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 13
Completed
Phase 1
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma Start of enrollment: 2013 Jan 08
Completed
Phase 3
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS Start of enrollment: 2013 Nov 01
Completed
Phase 1
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia Start of enrollment: 2014 Jan 30
Active, not recruiting
Phase 1, Phase 2
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Aug 07
Active, not recruiting
Phase 1
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia Start of enrollment: 2014 Aug 18
Active, not recruiting
Phase 1
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2014 Dec 29
Active, not recruiting
Phase 1
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia Start of enrollment: 2014 Sep 08
Active, not recruiting
Phase 2
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma Start of enrollment: 2015 Feb 01
Completed
Phase 1
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Start of enrollment: 2015 Mar 02
Active, not recruiting
Phase 2
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL Start of enrollment: 2014 Dec 22
Active, not recruiting
Phase 1
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread Start of enrollment: 2015 Mar 12
Terminated
Phase 2
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies Start of enrollment: 2014 Dec 20
Active, not recruiting
Phase 1, Phase 2
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Start of enrollment: 2015 Jan 12
Active, not recruiting
Phase 2
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer Start of enrollment: 2015 Apr 01
Completed
Phase 2
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Start of enrollment: 2015 Feb 20
Active, not recruiting
Phase 1, Phase 2
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2015 May 01
Completed
Phase 2
ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate Start of enrollment: 2015 Apr 01
Completed
Phase 2
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma Start of enrollment: 2015 Aug 01
Withdrawn
Phase 3
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer Start of enrollment: 2015 May 01
Completed
Phase 2
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma Start of enrollment: 2015 May 01
Completed
Phase 2
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2015 Jun 16
Completed
Phase 1
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Start of enrollment: 2015 Jun 26
Active, not recruiting
Phase 3
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2015 Jul 28
Active, not recruiting
Phase 3
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer Start of enrollment: 2015 Oct 13
Terminated
Phase 2
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) Start of enrollment: 2016 Jan 25
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Is there still a role for surgery in bleeding portal hypertension?
Henderson JM Yang Y > ;Nat Clin Pract Gastroenterol Hepatol . 2005 Jun
Image of the month. Focal nodular hyperplasia.
Yolanda Y.L. Yang, Robert J. Rothbaum, William C. Chapman, Martin D. Jendrisak, Surendra Shenoy, Niraj M. Desai, Jeffrey A. Lowell> ;Archives of Surgery. 2004 Jan 1
A brain-enriched polypyrimidine tract-binding protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing.
Polydorides AD Okano HJ Yang YY Stefani G Darnell RB > ;Proc Natl Acad Sci U S A . 2000 Jun 6
Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability.
Jensen KB Dredge BK Stefani G Zhong R Buckanovich RJ Okano HJ Yang YY Darnell RB > ;Neuron . 2000 Feb
Crystal structures of Nova-1 and Nova-2 K-homology RNA-binding domains.
Lewis HA Chen H Edo C Buckanovich RJ Yang YY Musunuru K Zhong R Darnell RB Burley SK > ;Structure . 1999 Feb 15
The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia.
Yang YY Yin GL Darnell RB > ;Proc Natl Acad Sci U S A . 1998 Oct 27
A quantitative study of environmental asbestos exposure in Honolulu.
Yang HY Wishart J Yang YY Lumeng J Paik YK > ;Hawaii Med J . 1998 Jun
Mouse chromosomal locations of nine genes encoding homologs of human paraneoplastic neurologic disorder antigens.
Fletcher CF Okano HJ Gilbert DJ Yang Y Yang C Copeland NG Jenkins NA Darnell RB > ;Genomics . 1997 Oct 15
The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies.
Buckanovich RJ Yang YY Darnell RB > ;J Neurosci . 1996 Feb 1
Join now to see all

Books/Book Chapters

Chapter: 27: Management of Portal Hypertension
Yang YY, Henderson JMEditors: Geroulakos G, van Urk H, Hobson II RW.Edition 2,
Chapter: 18: Biliary Surgery
Yang YY, Strasberg SMEditors: Klingensmith ME, Amos KD, Green DW, Halpin VJ, Hunt, SR.Edition 4,

Abstracts/Posters

Dose-limiting toxicity: how to understand DLT in oncology clinical trials and approach challenges with modern agents and combination therapies
Yang YY, (invited speaker; oral presentation) World Drug Safety Congress Americas 2019, Philadelphia, PA, 2019
MINI TREK Coronary Dilatation Catheter in predilatation of chronic total occlusion (CTO) lesions: Results from the EXPERT CTO multicenter clinical trial.
Kini AS, Karmpaliotis D, Tummala PE, Grantham JA, Nicholson WJ, Lembo NJ, Yang YY, Wang J, Rutledge DE, Kandzari DE, (poster) Society for Cardiovascular Angiography and Interventions 2013 Scientific Sessions, Orlando, FL [abstract published in Catheter Cardiovasc Interv 81(S1):S48-S49], 2013
Procedural effectiveness of HT PILOT and HT PROGRESS Guide Wires in chronic total occlusion (CTO) revascularization: Results from the EXPERT CTO multicenter clinical t...
Kini AS, Karmpaliotis D, Tummala PE, Moses JW, Grantham JA, Lembo NJ, Yang YY, Wang J, Rutledge DE, Kandzari DE, (poster) Society for Cardiovascular Angiography and Interventions 2013 Scientific Sessions, Orlando, FL [abstract published in Catheter Cardiovasc Interv 81(S1):S46], 2013
Quality of life and diabetic control after total pancreatectomy, a modern case review.
Tan MC, Tobin GS, Yang YY, Drebin JA, Hawkins WG, Strasberg SM, Linehan DC, (oral presentation, presented by M. Tan) 2005 American Hepato-Pancreato-Biliary Association Congress, Fort Lauderdale, FL, 2005
Analysis of intraoperative frozen section results in intraductal papillary mucinous tumor of the pancreas.
Yang YY, Wang HL, Drebin JA, Strasberg SM, Linehan DC, (oral presentation) 6th World Congress of the International Hepato-Pancreato-Biliary Association, Washington, DC. [abstract published in HPB 2004;6(S1):40], 2004
A novel brain-enriched PTB protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing.
Polydorides AD, Okano HJ, Yang YY, Stefani G, Darnell RB, (poster) Fifth annual meeting of the RNA Society, 2000
Functional studies of the neuron-specific RNA-binding protein Nova-1.
Buckanovich RJ, Zhong R, Yang YY, Jensen KB, Darnell RB, (poster) Eukaryotic mRNA Processing, Cold Spring Harbor Symposium, Cold Spring Harbor, NY, 1997
Interactions between Nova and Hu neuron-specific RNA-binding proteins.
Yang YY, Okano HJ, Darnell RB, (poster) RNA '97 (The RNA Society meeting), Banff, Canada, 1997
Mice deficient in the neuron-specific RNA-binding protein Nova-1.
Zhong R, Okano HJ, Yang YY, Yang C, Darnell RB, (poster) RNA '97 (The RNA Society meeting), Banff, Canada, 1997
Nova paraneoplastic disease antigens: Neuron-specific and sequence-specific RNA binding proteins.
Yang YY, Buckanovich RJ, Darnell RB, (poster) Post-transcriptional RNA processing, Keystone Symposium, Hilton Head Island, SC, 1996
Nova-2: A new neuron-specific RNA-binding protein associated with paraneoplastic opsoclonus-myoclonus-ataxia.
Yang YY, Buckanovich RJ, Darnell RB, (poster) Society for the Advancement of Neuroscience Annual Conference, Miami, FL, 1994
Join now to see all

Research History

Consultant - MedSci ConsultingClinical research, clinical development, medical safety science for multiple clinical trials, and drug safety and pharmacovigilance throughout product development life cycle.2020 - Present
Senior Director, Medical Safety Science - Acerta PharmaDrug safety and pharmacovigilance throughout product development life cycle.2015 - 2019
Drug Safety Scientist - Genentech/RocheDrug safety and pharmacovigilance throughout product development life cycle.2013 - 2015
Principal Clinical Research Scientist - Abbott VascularClinical science, research, and development for multiple clinical trials.2011 - 2013
Investigator - Washington University School of Medicine in St. LouisInvestigator in research protocol: Case series of patients after total pancreatectomy.2004 - 2005
Principal Investigator - Washington University School of Medicine in St. LouisPrincipal Investigator in research protocol: Accuracy of frozen section vs. final pathology for intraductal papillary mucinous tumors of the pancreas.2003 - 2004
Course Assistant - Cold Spring HarborCourse Assistant for Molecular Cloning of Neural Genes summer course. Provided general molecular biology laboratory supervision and teaching to course attendees.1997 - 1997
Doctor of Philosophy - The Rockefeller UniversityPhD under Dr. Robert Darnell, Laboratory of Molecular Neuro-Oncology. Doctoral thesis: Nova-2, a new paraneoplastic neurologic disease antigen: Multiple functions based on localization in neurons and specific protein and RNA interactions.1993 - 1997
Research Assistant - Pomona CollegeResearch Assistant under Dr. Teresa Strecker, Department of Biology. Investigated Drosophila embryo vitelline membrane permeability to various dyes and teratogenic drugs.1991 - 1991
Biological Aide - National Institutes of HealthBiological Aide under Dr. Stephen Straus and Dr. Jeffrey Ostrove, Medical Virology Section. Investigated the effects of deletion mutations on the trans-activating genes of the varicella-zoster virus.1990 - 1990
Research Assistant - University of Hawaii Medical SchoolResearch Assistant under Dr. Hong-Yi Yang, Department of Pathology. Investigated the asbestos content of lung tissue in the general population of Oahu.1989 - 1989
Research Assistant - Pomona CollegeResearch Assistant under Dr. Larry Cohen, Department of Biology. Investigated the proteolytic enzyme papain and provided general technical assistance.1988 - 1989
Research Assistant - University of Hawaii at ManoaResearch Assistant under Dr. Craig Jensen, Department of Chemistry. Investigated the effects of varying fluorine content in ceramic superconductors.1988 - 1988

Industry Relationships

Founder/Owner & Independent Consultant, MedSci Consulting Inc.2020 - Present
Senior Director, Medical Safety Science, Acerta Pharma2015 - 2019
Drug Safety Scientist, Genentech/Roche2013 - 2015
Principal Clinical Research Scientist, Abbott Vascular2011 - 2013

YolandaY.YangMDPhD

Dr. Yang is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Research History

Industry Relationships

Viewing the full profile is available to verified healthcare professionals only.